These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 34841527)
1. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1? Vuilleumier N; Pagano S; Ludewig B; Schmiedeberg K; Haller C; von Kempis J; Rubbert-Roth A Eur J Clin Invest; 2022 Feb; 52(2):e13713. PubMed ID: 34841527 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Jaycox JR; Lucas C; Yildirim I; Dai Y; Wang EY; Monteiro V; Lord S; Carlin J; Kita M; Buckner JH; Ma S; Campbell M; Ko A; Omer S; Lucas CL; Speake C; Iwasaki A; Ring AM Nat Commun; 2023 Mar; 14(1):1299. PubMed ID: 36894554 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Pagano S; Yerly S; Meyer B; Juillard C; Suh N; Le Terrier C; Daguer JP; Farrera-Soler L; Barluenga S; Piumatti G; Hartley O; Lemaitre B; Eberhardt CS; Siegrist CA; Eckerle I; Stringhini S; Guessous I; Kaiser L; Pugin J; Winssinger N; Vuilleumier N Eur J Clin Invest; 2021 Nov; 51(11):e13661. PubMed ID: 34324704 [TBL] [Abstract][Full Text] [Related]
4. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232 [TBL] [Abstract][Full Text] [Related]
5. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. Giannoccaro MP; Vacchiano V; Leone M; Camilli F; Zenesini C; Panzera I; Balboni A; Tappatà M; Borghi A; Salvi F; Lugaresi A; Rinaldi R; Di Felice G; Lodi V; Lazzarotto T; Liguori R; J Neurol; 2022 Aug; 269(8):4000-4012. PubMed ID: 35503375 [TBL] [Abstract][Full Text] [Related]
6. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643 [TBL] [Abstract][Full Text] [Related]
7. Newborns' passive humoral SARS-CoV-2 immunity following heterologous vaccination of the mother during pregnancy. Gloeckner S; Hornung F; Heimann Y; Schleussner E; Deinhardt-Emmer S; Loeffler B; Zoellkau J Am J Obstet Gynecol; 2022 Feb; 226(2):261-262. PubMed ID: 34648744 [No Abstract] [Full Text] [Related]
8. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose. Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073 [TBL] [Abstract][Full Text] [Related]
9. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
10. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine. Wang M; Wen W; Zhou M; Wang C; Feng ZH Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268 [No Abstract] [Full Text] [Related]
12. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis. Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409 [TBL] [Abstract][Full Text] [Related]
13. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880 [TBL] [Abstract][Full Text] [Related]
14. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients. Hirama T; Akiba M; Shundo Y; Watanabe T; Watanabe Y; Oishi H; Niikawa H; Okada Y J Infect Chemother; 2022 Aug; 28(8):1153-1158. PubMed ID: 35599079 [TBL] [Abstract][Full Text] [Related]
17. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289 [TBL] [Abstract][Full Text] [Related]
18. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis. Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863 [TBL] [Abstract][Full Text] [Related]
19. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A; Front Immunol; 2022; 13():868915. PubMed ID: 35432335 [TBL] [Abstract][Full Text] [Related]
20. Study of humoral and cellular immunity in vaccinated with mRNA-1273. Gutiérrez-Bautista JF; López-Nevot MÁ; Gómez-Vicente E; Quesada T; Marín EM; Rodríguez A; Rodríguez AI; Rodríguez-Granger J; Cobo F; Sampedro A APMIS; 2022 May; 130(5):261-269. PubMed ID: 35196403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]